#zepbound
GLP-1 Weight Loss Drugs Lift Pharma Profits, But Deloitte Warns of Bubble Risk
GLP-1 Drugs Drive Pharma Growth GLP-1 weight loss drugs are powering a sharp rebound in pharma R&D returns, but analysts warn the boom may be creating a risky “bubble effect” across the sector. According to Deloitte’s latest pharma innovation analysis, R&D returns among the world’s top 20 drugmakers have climbed to 7%, driven largely by obesity and diabetes treatments such as GLP-1 drugs. Obesity Drugs Overtake Oncology
GLP-1 Weight Loss Drugs Lift Pharma Profits, But Deloitte Warns of Bubble Risk
GLP-1 Drugs Drive Pharma Growth GLP-1 weight loss drugs are powering a sharp rebound in pharma R&D returns, but analysts warn the boom may be creating a risky “bubble effect” across the sector. According to Deloitte’s latest pharma innovation analysis, R&D returns among the world’s top 20 drugmakers have climbed to 7%, driven largely by obesity and diabetes treatments such as GLP-1 drugs. Obesity Drugs Overtake Oncology
Pharma executive collapses during Trump’s Oval Office event on obesity drug prices
A senior pharmaceutical executive collapsed during an Oval Office event where former U.S. President Donald Trump was announcing a new initiative to reduce the prices of obesity drugs. The incident caused a sudden interruption to the live broadcast of the announcement, which was centered on a major agreement between the Trump administration and leading pharmaceutical manufacturers. According to eyewitnesses, the executive, later identified as Gordon Findlay of Novo Nordisk, lost his
Pharma executive collapses during Trump’s Oval Office event on obesity drug prices
A senior pharmaceutical executive collapsed during an Oval Office event where former U.S. President Donald Trump was announcing a new initiative to reduce the prices of obesity drugs. The incident caused a sudden interruption to the live broadcast of the announcement, which was centered on a major agreement between the Trump administration and leading pharmaceutical manufacturers. According to eyewitnesses, the executive, later identified as Gordon Findlay of Novo Nordisk, lost his









